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Of 176 invasive Streptococcus pneumoniae isolates 
from children in Malawi, common serotypes were 1 (23%), 
6A/B (18%), 14 (6%), and 23F (6%). Coverage with the 
7-valent pneumococcal conjugate vaccine (PCV) was 39%; 
PCV10 and PCV13 increased coverage to 66% and 88%, 
respectively. We found chloramphenicol resistance in 27% 
of isolates and penicillin nonsusceptibility in 10% (by using 
meningitis breakpoints); all were ceftriaxone susceptible.
S
treptococcus pneumoniae causes a spectrum of 
disease, ranging from relatively mild otitis media to 
life-threatening pneumonia, meningitis, and septicemia. 
Recent estimates suggest that pneumococcal disease is 
responsible for 1 million deaths annually, >800,000 of 
which are in children <5 years of age in the developing 
world (1). Developing countries have the highest incidence 
of pneumococcal disease, and the spread of HIV, which 
increases the risk for pneumococcal disease up to 40-fold, 
has exacerbated the situation (2). In Malawi, in southern 
Africa, S. pneumoniae is 1 of the most common organisms 
isolated from blood and cerebrospinal ﬂ  uid (CSF) cultures 
of children admitted to the hospital, and the case-fatality 
rate for invasive pneumococcal disease (IPD), pneumonia, 
septicemia, and meningitis is ≈25% (3,4).
The successful introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7) in several 
industrialized nations has led to plans to extend its use to 
sub-Saharan Africa (2). PCV7 contains the most commonly 
isolated 7 serotypes from IPD in children in the United 
States before vaccine implementation. However, these 7 
serotypes account for <50% of IPD isolates from children 
in Africa (5). Surveillance of circulating serotypes is 
therefore essential information for developing policy about 
vaccine introduction.
In the United States, PCV7 has successfully reduced 
the incidence of IPD and antimicrobial drug resistance in 
vaccine serotypes; however, this decrease paralleled an 
increase in the incidence of IPD caused by nonvaccine 
serotypes, among which antimicrobial drug resistance 
is increasing (6). Resistance to penicillin and other 
antimicrobial agents in pneumococci complicates clinical 
management (7). Previous data from Malawi suggest that 
penicillin resistance in IPD is relatively low (8–11).
We report the serotypes of pneumococcal isolates from 
febrile children admitted to the largest hospital in Blantyre, 
Malawi, during April 2004–October 2006. We also report 
susceptibilities to antimicrobial drugs used to treat IPD.
The Study
We studied S. pneumoniae isolated from the blood 
or CSF of children 2 months–16 years of age, admitted 
to Queen Elizabeth Central Hospital (QECH), the main 
referral hospital for southern Malawi, during April 2004–
October 2006. Blood cultures were performed for all 
children admitted with signs of pneumonia or meningitis, 
and CSF cultures were performed for all children with 
signs suggestive of meningitis during the collection 
period. QECH admits ≈25,000 children and 17,000 adults 
annually and serves a population of ≈1 million. It is a 
government-funded teaching and referral hospital with 
1,250 beds, although the total number of patients can 
exceed 2,000. Participants were recruited to studies of the 
host and bacterial factors determining outcome in invasive 
pneumococcal infection (3). The College of Medicine 
Research Committee, Malawi, and The Liverpool School 
of Tropical Medicine Local Research Ethics Committee 
granted ethics approval for this study.
Blood and CSF were processed by standard 
microbiological methods (3). S. pneumoniae isolates were 
identiﬁ  ed by colony morphology and α-hemolysis and then 
conﬁ  rmed by Gram staining and determination of optochin 
susceptibility (Oxoid, Basingstoke, UK). Isolates were 
stored at –80°C after primary isolation in bead and broth 
cryopreservers (Pro-Lab Diagnostics, Richmond Hill, ON, 
Canada). Isolates were transported to Liverpool and later 
subcultured for serotyping and MIC determinations.
Serotyping was performed by multiplex PCR as 
described by Pai et al. (12). MICs were determined by 
the Etest (AB Biodisk, Solna, Sweden) according to 
the manufacturer’s recommendation. Benzyl penicillin, 
ceftriaxone, and chloramphenicol were tested. S. 
pneumoniae ATCC 49619 was used as a quality control 
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Antimicrobial drug susceptibility breakpoints were deﬁ  ned 
according to Clinical and Laboratory Standards Institute 
criteria (13).
We compared categorical values using Fisher exact test. 
A p value of <0.05 was considered signiﬁ  cant. Statistical 
analysis was performed by using Stata 10 (StataCorp, 
College Station, TX, USA). When calculating serotype 
coverage, we assumed serotype 6A/B cross-protection for 
PCV7 and the 10-valent pneumococcal vaccine (PCV10).
A total of 180 isolates were collected from children 
admitted to QECH during the study period: 37 (21%) from 
CSF and 143 (79%) from blood. Four isolates did not 
remain viable during storage; 176 isolates were available 
for serotyping and MIC determination. Of these, 95 (54%) 
were from boys. Median age of patients was 2.5 years 
(range 2 months–14 years; interquartile range 8 months–7 
years). Of the isolates studied, 100 (57%) were from HIV-
positive children, and 71 (40%) were from HIV-negative 
children. Testing was declined for 5 (3%) children. The 
case-fatality rate was 25% for HIV-positive children and 
21% for HIV-negative children (p = 0.68). Serotypes 1 
and 6A/6B predominated, accounting for 23% and 18% 
of isolates, respectively (Table 1). Of the 176 isolates, 69 
(39%), 116 (66%), and 154 (88%) had a serotype included 
in PCV7, PCV10, and PCV13, respectively.
Clinical and Laboratory Standards Institute breakpoints 
for penicillin and ceftriaxone varied for meningitis or 
nonmeningitis infections (Table 2). Using the meningitis 
breakpoints, we found 158 (90%) isolates were susceptible 
to penicillin, and 18 (10%) were resistant to penicillin. 
However, according to non-meningitis breakpoints, all 
isolates were penicillin susceptible. Of the 150 children 
with meningitis, isolates from 16 (10.7%) patients 
were resistant by meningitis breakpoints. All isolates 
were susceptible to ceftriaxone by both breakpoints. 
Chloramphenicol resistance was present in 47 (27%) of 
isolates. Chloramphenicol-resistant pneumococci were 
isolated from 28 (39%) of the 71 HIV-negative children 
and 18 (18%) of the 100 HIV-positive children (p = 
0.0027). The 2 groups did not differ signiﬁ  cantly in levels 
of resistance to the other antimicrobial agents.
Conclusions
Our study describes recent pneumococcal serotyping 
and antimicrobial drug susceptibility data for children in 
Malawi. Serotype distributions suggest that PCV7 would 
provide poor potential coverage for these children; PCV7 
includes only 39% of serotypes identiﬁ  ed. This information 
is supported by a previous study that found that PCV7 
would cover 41% of invasive pneumococcal isolates from 
children (14). Serotypes 1 and 5, long regarded as essential 
in vaccines for use in sub-Saharan Africa, accounted for 
23% and 1% of all isolates in this study, respectively. 
Our data suggest that use of the 13-valent vaccine, which 
includes serotypes 1 and 5 and is due to be introduced into 
Malawi in late 2011, will substantially increase vaccine 
coverage. The nontypeable isolates included in the study 
may have been typeable by an alternative method. However, 
the serotyping method used includes all serotypes in PCV7, 
PCV10, and PCV13.
Our study is not a formal epidemiologic study because 
it did not comprise a true random selection of isolates; 
however, QECH is the only public hospital in this area 
and most children admitted to the hospital live within the 
local community. Furthermore, we studied all consecutive 
cases during the study period, both severe and nonsevere. 
The sample of pneumococcal disease in children studied 
is therefore likely to be representative of the incidence of 
disease in this area.
The high proportion of blood cultures studied implies 
that pneumonia was the primary clinical diagnosis, however, 
most had meningitis. Penicillin is the ﬁ  rst-line treatment for 
pneumonia and presumed sepsis at QECH, and ceftriaxone 
is the ﬁ   rst-line treatment for suspected meningitis. Use 
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Table 1. Serotypes of Streptococcus.pnemoniae isolated from 
children at Queen Elizabeth Central Hospital, Blantyre, Malawi, 
2004–2006 
Serotype 
No. (%) 
isolates
HIV serostatus, no. (%) 
Positive Negative Declined
1 41 (23)  16 (16)  24 (34)  1 (20) 
6A/6B* 31 (18)  21 (21)  9 (13)  1 (20) 
14* 11 (6)  8 (8)  3 (4)  0
23F*  11 (6)  7 (7)  4 (6)  0
12F  10 (6)  4 (4)  6 (8)  0
19F*  9 (5)  6 (6)  3 (4)  0
Sg18* 6 (3)  3 (3)  3 (4)  0
4* 5 (3)  5 (5)  0 0
7f 4 (2)  1 (1)  3 (4)  0
10A 3 (2)  2 (2)  1 (1)  0
16F  3 (2)  3 (3)  0 0
33F  3 (2)  1 (1)  2 (3)  0
35F  3 (2)  2 (2)  1 (1)  0
3 2 (1)  2 (2)  0 0
5 2 (1)  0 2 (3)  0
9V* 2 (1)  1 (1)  0 1 (20) 
14/4 2 (1)  1 (1)  1 (1)  0
15a 2 (1)  1 (1)  1 (1)  0
19a 2 (1)  1 (1)  0 1 (20) 
7c 1 (1)  0 1 (1)  0
8 1 (1)  0 1 (1)  0
34 1 (1)  1 (1)  0 0
11a 1 (1)  1 (1)  0 0
17f 1 (1)  1 (1)  0 0
35B 1 (1)  0 0 1 (20) 
Not typeable  18 (10)  12 (12)  6 (8)  0
Total 176 100 71 5
*Serotypes in 7-valent pneumococcal conjugate vaccine: 4, 6B, 9V, 14, 
18C, 19F, 23F. PCV10 adds serotypes 1, 5, and 7F. PCV13 adds 
serotypes 3, 6A, and 19A. Streptococcus pneumoniae in Children
of non-meningitis breakpoints in this study demonstrates 
no penicillin resistance. The susceptibility of all isolates 
to ceftriaxone conﬁ   rms its suitability as a second-line 
treatment. Chloramphenicol resistance rates were high at 
27%. The resistance levels reported here remain similar to 
those reported previously (8–11). Levels of resistance are 
comparable to those in other studies in sub-Saharan Africa 
but less than in many other areas in the world (7), possibly 
because antimicrobial drug use in Malawi is lower than that 
of other countries.
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Table 2. Antimicrobial drug susceptibilities of Streptococcus pneumoniae isolates from children at Queen Elizabeth Central Hospital, 
Blantyre, Malawi, 2004–2006* 
Antimicrobial drug 
MIC, mg/L  No. (%) isolates*  Breakpoint values 
Minimum Maximum MIC50 MIC90 GM S I R S I R
Benzyl penicillin 
  Meningitis breakpoints  <0.016  0.500  <0.016 0.094  0.025  156 (90)  – 18 (10)  <0.06 – >0.12
  Nonmeningitis breakpoints  <0.016  0.500  <0.016 0.094  0.025  176 (100) 0  0 <2.0 4.0 >8.0
Ceftriaxone 
  Meningitis breakpoints  <0.016  0.250  <0.016 0.064  0.025  176 (100) 0  0 <0.5 1.0 >2.0
  Nonmeningitis breakpoints  <0.016  0.500  <0.016 0.094  0.025  176 (100) 0  0 <1.0 2.0 >4.0
Chloramphenicol 0.380  30.000  3.000  25.000 4.660  129 (73)  – 47 (27)  <4.0 – >8.0
*MIC50, 50% MIC; MIC90, 90% MIC; GM, geometric mean; S, susceptible; I, intermediate; R, resistant; –, no intermediate resistance values for these 
antimicrobial drugs, according to Clinical and Laboratory Standards Institute definitions.  